Dostarlimab
- TRADE NAME: Jemperli (GSK)
- INDICATIONS:
Treatment of advanced endometrial cancer following prior treatment with a platinum-containing drug regimen.
- CLASS: Biologic, Immune checkpoint inhibitor, Monoclonal antibody, Programmed death receptor-1 (PD-1) inhibitor
- HALF-LIFE: 25.4 days
FDA APPROVAL DATE: 4/22/2021
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:None known
Based on its mechanism of action, dostarlimab can cause fetal harm when administered in pregnancy. Contraception is advised.
Dostarlimab may cause immune-mediated adverse reactions.
Please login to see the rest of this drug profile
SKIN.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric